Phase 3 Alemtuzumab Pediatric MS Trial Terminated (NCT03368664)

A Phase 3 clinical trial evaluating alemtuzumab has been marked as terminated, according to a status update dated August 4, 2026. The study, registered as NCT03368664, was titled "A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT." It examined alemtuzumab in pediatric patients with relapsing-remitting multiple sclerosis who showed disease activity while on a prior disease-modifying therapy. The trial was designated as a Phase 3 study. According to the available record, its current status is listed as terminated. No results, efficacy data, or safety findings were provided in this update. The reason for termination was not specified in the event data. This update pertains specifically to the alemtuzumab trial record and does not include additional information about glatiramer or any comparator therapies referenced in the broader study context. Readers seeking background on trial design, prior status, or related documentation can consult the official registry listing linked with this record. For more context on glatiramer as a compound, readers can consult the compound overview.